Focus
rhybelsus
Ozempic’s Sister Drug Reduces Cardiovascular Risk by 14 Percent in Large-Scale Trial
Learn about the study’s possible impact on treatment strategies.
|
Ozempic’s Sister Drug Reduces Cardiovascular Risk by 14 Percent in Large-Scale Trial
Learn about the study’s possible impact on treatment strategies.
|